American Journal of Psychiatry

Although the cognitive model of depression has evolved appreciably since its first formulation over 40 years ago, the potential interaction of genetic, neurochemical, and cognitive factors has only recently been demonstrated. Combining findings from ...

https://doi.org/10.1176/appi.ajp.2008.08050721

pdf

abstract

full text

SAVE ARTICLE

Article

Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia

Publication date: 01 August 2008

Pages978–987

Objective: This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Method: CATIE ...

https://doi.org/10.1176/appi.ajp.2008.07111713

Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [ ¹⁸ F]Fallypride PET Study

Publication date: 01 August 2008

Pages988–995

Objective: Aripiprazole at clinically effective doses occupies some 90% of striatal dopamine 2 and 3 (D ₂ /D ₃ ) receptors. In order to further characterize its extrastriatal and time-dependent binding ...

https://doi.org/10.1176/appi.ajp.2008.07101574

Reduced Evoked Gamma Oscillations in the Frontal Cortex in Schizophrenia Patients: A TMS/EEG Study

Publication date: 01 August 2008

Pages996–1005

Objective: Transcranial magnetic stimulation (TMS) combined with high-density electroencephalography (EEG) can be used to directly examine the properties of thalamocortical circuits in the brain without engaging an individual in cognitive or ...

https://doi.org/10.1176/appi.ajp.2008.07111733

Association of Dorsolateral Prefrontal Cortex Dysfunction With Disrupted Coordinated Brain Activity in Schizophrenia: Relationship With Impaired Cognition, Behavioral Disorganization, and Global Function

Publication date: 01 August 2008

Pages1006–1014

Objective: Although deficits in cognitive control are thought to contribute to the diverse cognitive and behavioral abnormalities in individuals with schizophrenia, the neural mechanisms underlying these deficits remain unclear. In this event-...

https://doi.org/10.1176/appi.ajp.2008.07060945

The Anatomy of First-Episode and Chronic Schizophrenia: An Anatomical Likelihood Estimation Meta-Analysis

Publication date: 01 August 2008

Pages1015–1023

Objective: The authors sought to map gray matter changes in first-episode schizophrenia and to compare these with the changes in chronic schizophrenia. They postulated that the data would show a progression of changes from hippocampal deficits ...

https://doi.org/10.1176/appi.ajp.2008.07101562

Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients

Publication date: 01 August 2008

Pages1024–1032

Objective: Comparisons of diffusion tensor imaging (DTI) data between first-episode and chronic schizophrenia patients assessed in different studies have led to the suggestion that the decreased fractional anisotropy observed in chronic ...

https://doi.org/10.1176/appi.ajp.2008.07101640

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Publication date: 01 August 2008

Pages1033–1039

Objective: There are significant unmet needs in the treatment of schizophrenia, especially for the treatment of cognitive impairment, negative syndrome, and cognitive function. Preclinical data suggest that agonists with selective affinity for ...

https://doi.org/10.1176/appi.ajp.2008.06091591

Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

Publication date: 01 August 2008

Pages1040–1047

Objective: Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of α ₇ -nicotinic receptors. Patients’ heavy ...

https://doi.org/10.1176/appi.ajp.2008.07071135